Edwards Lifesciences Corp EW revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Edwards Lifesciences Corp reported revenue across 3 products and services; the largest, Transcatheter Aortic Valve Replacement, was $4.49B, 74.0% of the filed sum (+9.3% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Transcatheter Aortic Valve Replacement$4.49B74.0%+9.3% yoy
- Surgical Heart Valve Therapy$1.03B17.0%+4.9% yoy
- Transcatheter Mitral And Tricuspid Therapies$551M9.1%+56.4% yoy
Members sum to the consolidated $6.07B for this period.
- Transcatheter Aortic Valve Replacement$1.2B72.6%+14.4% yoy
- Surgical$276M16.8%+10.1% yoy
- Transcatheter Mitral And Tricuspid Therapies$175M10.6%+52.0% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.